Submitted by kBLASTER Team on
ANDOVER, MA. – Royal Philips (NYSE: PHG AEX: PHIA) today announced that it received 510(k) clearance from the U.S.A. Food and Drug Administration (FDA) to market its Avalon CL Fetal Monitoring solution (Avalon CL). The solution provides consistent monitoring of the mother and child, without the burden of managing cables, allowing mothers more freedom of movement during labor. The product joins Philips' existing portfolio of mobility solutions designed for advanced monitoring and connected care across the health continuum, from healthy living and prevention, to diagnosis, treatment, recovery and home care.
Go to kBLASTER for FDA 510(k) predicate search with effective result management to build your successful 510(k) clearance strategy.